Hypertrophic cardiomyopathy (HCM) is among the most common inherited forms of cardiomyopathy, with estimated prevalence of at least 1 in 500 people, affecting males and females equally given autosomal dominant transmission. 1 The vast majority of individuals with HCM are expected to enjoy a normal lifespan and, thus, survival through child-bearing age. 2 Despite overall favourable outcomes with modern treatment and early recognition of disease through cascade clinical screening and genotyping of often asymptomatic relatives, adverse events are known to occur during times of physiological stress including vigorous exercise and pregnancy. [3] [4] [5] In this issue of the journal, Goland et al. report maternal and foetal outcomes from an international cohort of women with HCM who entered the ROPAC database. 6 Sixty women were included, the majority of whom were relatively healthy; only a few had prior septal reduction therapy or advanced NYHA functional class. For inclusion, left ventricular wall thickness of > _15 mm was required. Unfortunately, neither genotyping nor family history information was available, and 14% of women included had antecedent hypertension, raising the possibility that not all subjects had true sarcomeric HCM. Indeed, in one case of foetal demise, the foetus was found to have cardiomyopathy as well, and a mitochondrial disease was suspected. Over a relatively short follow-up period of 6 months after delivery, there were no maternal deaths and only three women experienced pregnancy loss. However, a major adverse cardiovascular event (MACE) defined as death, heart failure, arrhythmia, or thromboembolic event occurred in 23%. As expected, those women who had NYHA functional class greater than or equal to II or signs of heart failure before pregnancy were at higher risk of MACE. Events occurred mostly in the third trimester or early post-partum. Interestingly, there was no difference in outcome between women with left ventricular outflow tract obstruction and those without obstruction. Historically, the presence of left ventricular outflow tract obstruction has been associated with higher rates of adverse events in HCM 7, 8 and may be exacerbated by valsalva and fluid shifts that can occur during labour and delivery. The left ventricular outflow tract gradient was not obtained quantitatively in this study and therefore the severity of obstruction was unknown. Arrhythmias occurred in 12% of the women, mostly ventricular in origin, and only one patient required a defibrillator early in the post-partum period. Obstetric complications included a significantly increased rate of emergent delivery via Caesarean section in women who experienced MACE and approximately a quarter of women in the cohort had premature births. The ROPAC database has been instrumental in understanding pregnancy outcomes in various forms of cardiovascular disease. Review of previous publications from ROPAC allows us to compare MACE in pregnant women with a variety of cardiac diseases including pulmonary hypertension, peripartum cardiomyopathy, congenital heart disease, ischaemic heart disease, and valvular heart disease including aortic stenosis. [9] [10] [11] [12] [13] [14] It is reassuring that pregnancy with HCM is certainly lower risk than pregnancy with idiopathic pulmonary arterial hypertension or peripartum cardiomyopathy. Nonetheless, the importance of symptom severity preceding pregnancy is apparent in all forms of cardiovascular disease, with NYHA functional class providing the bulk of risk stratification in the cohorts studied. An algorithm for management of HCM in pregnancy based on hemodynamic changes is outlined in Figure 1 . In addition to pre-conception counselling of patients about the risk of maternal cardiac complications, it is critical to educate women with HCM regarding the risk of genetic transmission to their offspring. The option of pre-conception genetic testing for HCM in order to facilitate pre-implantation genetic diagnosis should also be offered to pregnant women if desired.
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